Skip to main content Skip to search Skip to main navigation

TEST Evaluation of the environmental risks of medicinal products (kostenlose Guideline) Kopie

0 reviews

Average rating of 0 out of 5 stars

Leave a review!

Share your experiences with other customers.

Product Information

Why Do You Need an Environmental Risk Assessment?

Nowadays, the application for placing a medicinal product for human use on the market requires an environmental risk assessment report. This report must be based on the instructions of the EMA's Guideline on the Environmental Risk Evaluation of Medicinal Products for Human Use (Doc. Ref. EMEA/CHMP/SWP/4447/00 corr. 2).

How to Obtain an Elemental Impurities Risk Assessment

The proven and successful collaboration between Azierta and GMP-Verlag Peither AG provides you with an economically priced alternative to conventional elemental impurities risk assessments. Following verification of the critical key data, we will be pleased to send you a binding, fixed price quote.

What You Get With Us

We provide comprehensive reports for the analysis and assessment of possible environmental risks of an API:

  • Evaluation procedures based on the current EU guideline: EMEA/CHMP/SWP/4447/00 corr 2.
  • Phase I: Estimation of exposure
  • Phase II: Environmental fate and effects analysis
  • Risk Assessment for each API using the latest version of the IQVIA database.
  • Specialised environmental toxicologists with extensive experience in new drug registrations.

Information Required for a Fixed Price Quote

To prepare a binding, fixed price quote, please provide the following information:

  • Company name and address
  • Name of the medicinal product
  • Country in which the product is to be sold
  • Maximum daily dose

Do you Have any Questions?

Cynthia Schulz, Vertrieb und Key Account für Toxkologische Gutachten beim GMP-Verlag

Talk to our customer advisors

Do you have any questions about our products and services? We are here to help.

Customer Reviews

0 reviews

Average rating of 0 out of 5 stars

Leave a review!

Share your experiences with other customers.

You may also be interested in the following products

Skip product gallery

k

OEL Categorisation | Sample Document

OEL Categorisation | Sample Document

Why do you need OEL categorisations? For every API, an upper limit on the acceptable concentration in workplace air has to be determined (OEL). For this determination, toxicological and pharmacological properties of the API are analysed and related to preventive measures.Our service includes extensive bibliographic researchOEL determination according to internationally accepted guidelines Categorisation with regard to the specific working conditions according to national requirements or SafeBridge® banding scheme This is what we need from you to prepare a quote Company name and address Name of the API Request a quote

delivery time appr. 2-5 workdays after receipt of payment
€0.00 net excl. VAT
How to implement ICH Q3D of elemental impurities in 5 steps (free manual)

How to implement ICH Q3D of elemental impurities in 5 steps (free manual)

Why do you need an elemental impurities risk assessment?As of June 2016, all new medicinal products have to be evaluated based on the ICH guideline Q3D on elemental impurities. As of December 2017, this guideline came into effect for already authorised medicinal products as well. Therefore, every authorised medicinal product has to be evaluated.How to obtain an elemental impurities risk assessment? The proven and successful collaboration between Dalia and GMP-Verlag Peither AG provides you with an economically priced alternative to conventional elemental impurities risk assessments. Following verification of the critical key data, we will be pleased to send you a binding, fixed price quote. Our service includes: Issuing of the elemental impurities risk assessment according to ICH Q3D guideline in English issued for the specific medicinal product according to ICH Q3D guideline issued by European toxicological experts This is what we need from you to prepare a binding, fixed price quote Company name and address Name of the medicinal product Completed questionnaire Request a quote

delivery time appr. 2-5 workdays after receipt of payment
€0.00 net excl. VAT

Recommended Articles

EDQM: Revised Guidance on Sister File Applications

EDQM: Revised Guidance on Sister File Applications

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has revised its Guidance on applications for “sister files” (PA/PH/CEP (09) 141). The revision is intended to support consistent application of the procedure and provide greater clarity on the classification and assessment of the corresponding CEP applications.
Read more
Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic has revised its guidance document “Mobile technologies” and added two new entries to the related questions and answers. The update follows an increasing number of queries regarding the details and placement of URLs, the positioning of QR codes and their captions.
Read more
EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA reported that Scholar Rock Netherlands withdrew its application for Isembyld after evaluation had progressed through the final round of questions. EMA’s provisional view was that the medicine could not be authorised because the applicant had not provided confirmation that the manufacturing site complied with EU GMP requirements.

Read more
France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

The French medicines agency ANSM has published an update on its “Longue vie aux médicaments” pilot project aimed at extending the shelf life of medicines. Fourteen pharmaceutical companies responded to the call for applications. The project covers a total of 73 medicines, including commonly used products containing paracetamol, levothyroxine, melatonin or lithium.
Read more
How is First Air Verified and Monitored During Aseptic Process Qualification?

How is First Air Verified and Monitored During Aseptic Process Qualification?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part I: Supplier Management

Outsourced Activities in the GDP Environment Part I: Supplier Management

Supplier management is the systematic management of a company´s relationship with its suppliers. It encompasses supplier qualification and customer audits as described in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

FDA: Draft Guidance on Assessing Container Closure Systems for Drugs and Biologics

On 14 August 2026, the US Food and Drug Administration (FDA) announced the publication of a new draft guidance document entitled ‘Container Closure Systems for Human Drugs and Biological Products’.

Read more
FDA: New FDA Commissioner Dr. Heidi Overton

FDA: New FDA Commissioner Dr. Heidi Overton

President Donald Trump has named White House aide Heidi Overton to lead the US Food and Drug Administration (FDA). Overton will fill the position previously held by Marty Makary, who left the agency in May. This announcement was made on Trump's Truth Social account on 19 August. Her nomination is subject to confirmation by the Senate.

Read more
IPEC: Stability Guide for Excipients has been Updated

IPEC: Stability Guide for Excipients has been Updated

The IPEC Stability Guide for Pharmaceutical Excipients has been updated and is now available as version 3 (2026), as announced on the IPEC (International Pharmaceutical Excipients Council) website.

Read more
EU: “Forever Chemicals” in a Conflict of Interests

EU: “Forever Chemicals” in a Conflict of Interests

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

Read more
Handover of Computerised Systems to the Operating Department

Handover of Computerised Systems to the Operating Department

The GMP-compliant handover of computerised systems to operations is a critical step in the Computer System Validation (CSV) lifecycle. Beyond go-live and hypercare, clearly defined responsibilities, comprehensive documentation and well-trained personnel are essential to maintaining a validated state throughout routine operation.
Read more
How is the Effectiveness of CAPAs Verified?

How is the Effectiveness of CAPAs Verified?

Here's the answer:
Read more
Previous
Next